Search

Your search keyword '"Horn, Leora"' showing total 895 results
Start Over Author "Horn, Leora"

Refine your results

more »

more »

more »

more »
895 results on '"Horn, Leora"'

3. Dedication

Author

Gillaspie, Erin Alexis, primary, Cass, Amanda S., additional, and Horn, Leora, additional

Published
2024
Full Text
View/download PDF

4. List of contributors

Author

Antonoff, Mara B., primary, Bryan, Darren S., additional, Cabanero, Michael, additional, Cass, Amanda S., additional, Cerullo, Marcelo, additional, David, Elizabeth, additional, Donington, Jessica S., additional, Farrow, Norma E., additional, Ferrara, Roberto, additional, Garassino, Marina C., additional, Gauthier, Marie-Pier, additional, Ghattas, Christian, additional, Gillaspie, Erin Alexis, additional, Gray, Jhanelle E., additional, Holden, Van K., additional, Horn, Leora, additional, Jonna, Sushma, additional, Lander, Eric M., additional, Leal, Ticiana A., additional, Leighl, Natasha B., additional, Liu, Stephen V., additional, Russo, Giuseppe Lo, additional, Montenegro, Gabriella Bravo, additional, Murthy, Vivek, additional, Nobel, Tamar B., additional, Padda, Sukhmani K., additional, Pal, Prodipto, additional, Pannu, Jasleen, additional, Puri, Sonam, additional, Revelo, Alberto, additional, Rosenberg, Stephen A., additional, Roy, Mohana, additional, Saltos, Andreas N., additional, Sharifi, Marina N., additional, Shemanski, Kimberly A., additional, Stinchcombe, Thomas E., additional, Tong, Betty Caroline, additional, Tsao, Ming-Sound, additional, and Viscardi, Giuseppe, additional

Published
2024
Full Text
View/download PDF

6. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Author

Beckermann, Kathryn E., Bestvina, Christine M., El Osta, Badi, Sanborn, Rachel E., Borghaei, Hossein, Lammers, Philip Edward, Selvaggi, Giovanni, Whisenant, Jennifer G., Heimann-Nichols, Ellen, Berry, Lynne, Hsu, Chih-Yuan, Shyr, Yu, Horn, Leora, and Wakelee, Heather

Published
2024
Full Text
View/download PDF

7. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Author

Burns, Laura, Hsu, Chih-Yuan, Whisenant, Jennifer G., Marmarelis, Melina E., Presley, Carolyn J., Reckamp, Karen L., Khan, Hina, Jo Fidler, Mary, Bestvina, Christine M., Brahmer, Julie, Puri, Sonam, Patel, Jyoti D., Halmos, Balazs, Hirsch, Fred R., Liu, Stephen V., Costa, Daniel B., Goldberg, Sarah B., Feldman, Lawrence E., Mamdani, Hirva, Puc, Matthew, Mansfield, Aaron S., Islam, Nahida, Scilla, Katherine A., Garassino, Marina C., Horn, Leora, Peters, Solange, Wakelee, Heather A., Charlot, Marjory, and Tapan, Umit

Published
2023
Full Text
View/download PDF

8. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

Author

Goldberg, Sarah B, Redman, Mary W, Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E, Horn, Leora, Chen, Everett H, Mashru, Sandeep H, Gettinger, Scott N, Melnick, Mary Ann, Herbst, Roy S, Baumgart, Megan A, Miao, Jieling, Moon, James, Kelly, Karen, and Gandara, David R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung Cancer, Lung, Cancer, Women's Health, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Adult, Afatinib, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cetuximab, ErbB Receptors, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Progression-Free Survival, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-free survival (PFS) in patients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or delaying resistance.MethodsPatients with EGFR-mutant NSCLC without prior treatment of advanced disease were enrolled in this phase II, multicenter trial and randomly assigned to receive afatinib 40 mg orally daily plus cetuximab 500 mg/m2 intravenously every 2 weeks or afatinib alone. The primary end point was PFS.ResultsBetween March 25, 2015 and April 23, 2018, 174 patients were randomly assigned, and 168 (83 on afatinib + cetuximab and 85 on afatinib) were eligible. There was no improvement in PFS in patients receiving afatinib plus cetuximab compared with afatinib alone (hazard ratio [HR], 1.01; 95% CI, 0.72 to 1.43; P = .94; median, 11.9 months v 13.4 months). Similarly, there was no difference in response rate (67% v 74%; P = .38) or overall survival (HR, 0.82; 95% CI, 0.50 to 1.36; P = .44). Toxicity was greater with the combination: grade ≥ 3 adverse events related to treatment occurred in 72% of patients receiving afatinib plus cetuximab compared with 40% of those receiving afatinib alone, most commonly rash and diarrhea. Dose reductions were more common in patients receiving the combination, and 30% of patients in this arm discontinued cetuximab due to toxicity. At interim analysis, there was insufficient evidence to support continued accrual, and the trial was closed.ConclusionsThe addition of cetuximab to afatinib did not improve outcomes in previously untreated EGFR-mutant NSCLC, despite recognized activity in the acquired resistance setting.

Published
2020

9. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Author

Patrinely, James, Young, Arissa, Quach, Henry, Williams, Grant, Ye, Fei, Fan, Run, Horn, Leora, Beckermann, Kathryn, Gillaspie, Erin, Sosman, Jeffrey, Friedman, Debra, Moslehi, Javid, and Johnson, Douglas

Subjects
Anti–PD-1, Checkpoint inhibitors, Lung cancer, Melanoma, Nivolumab, Pembrolizumab, Quality of life, Renal cell carcinoma, Survivorship, Toxicities, Aged, Antineoplastic Agents, Immunological, B7-H1 Antigen, Body Composition, Female, Functional Status, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Neoplasms, Nutritional Status, Programmed Cell Death 1 Receptor, Progression-Free Survival, Quality of Life, Retrospective Studies, Survivors, Time Factors
Abstract

AIM: Antibodies to programmed death-1 receptor and its ligand (anti-PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti-PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti-PD-1/PD-L1. METHODS: We assessed 217 patients who received anti-PD-1/PD-L1 for melanoma, renal cell carcinoma or non-small-cell lung carcinoma between 2009 and 2017, with survival greater than two years after treatment. Patient and tumour characteristics, immune-related adverse events (irAEs), cardiometabolic parameters (glucose, blood pressure, body mass index [BMI]), body composition (using automated body composition analyser, computed tomography and Slice-o-matic software) and HRQoL outcomes were tracked. RESULTS: Among the included patients, most were men (70.3%) and at anti-PD-1/PD-L1 initiation had an average age of 61.0 years and median BMI of 28.5. Median overall survival was not reached; 33 (15.2%) died during the follow-up primarily from progressive cancer (n = 28). At the last follow-up, most patients Eastern Cooperative Oncology Group performance status was 0 (38%) or 1 (41%). There was no difference in blood pressure, glucose or BMI from baseline to two years after treatment initiation. Body composition showed increased adiposity (p = 0.05), skeletal muscle mass (p = 0.03) and skeletal muscle gauge (p = 0.04). We observed chronic irAEs at the last follow-up including hypothyroidism (10.6%), arthritis (3.2%), adrenal insufficiency (3.2%) and neuropathy (2.8%). New diagnoses of type 2 diabetes (6.5%) and hypertension (6.0%) were observed, with uncertain relationship to anti-PD-1/PD-L1. Patient-reported outcomes compared favourably with cancer and general populations, although younger age (p = 0.003) and need for subsequent therapy (p = 0.03) were associated with worse HRQoL outcomes. CONCLUSION: Durable responses to anti-PD-1/PD-L1 therapy and favourable HRQoL outcomes are encouraging. Chronic events may be more common than previously thought although no clear chronic adverse cardiometabolic effects were observed.

Published
2020

10. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Author

Whisenant, Jennifer G., Baena, Javier, Cortellini, Alessio, Huang, Li-Ching, Lo Russo, Giuseppe, Porcu, Luca, Wong, Selina K., Bestvina, Christine M., Hellmann, Matthew D., Roca, Elisa, Rizvi, Hira, Monnet, Isabelle, Boudjemaa, Amel, Rogado, Jacobo, Pasello, Giulia, Leighl, Natasha B., Arrieta, Oscar, Aujayeb, Avinash, Batra, Ullas, Azzam, Ahmed Y., Unk, Mojca, Azab, Mohammed A., Zhumagaliyeva, Ardak N., Gomez-Martin, Carlos, Blaquier, Juan B., Geraedts, Erica, Mountzios, Giannis, Serrano-Montero, Gloria, Reinmuth, Niels, Coate, Linda, Marmarelis, Melina, Presley, Carolyn J., Hirsch, Fred R., Garrido, Pilar, Khan, Hina, Baggi, Alice, Mascaux, Celine, Halmos, Balazs, Ceresoli, Giovanni L., Fidler, Mary J., Scotti, Vieri, Métivier, Anne-Cécile, Falchero, Lionel, Felip, Enriqueta, Genova, Carlo, Mazieres, Julien, Tapan, Umit, Brahmer, Julie, Bria, Emilio, Puri, Sonam, Popat, Sanjay, Reckamp, Karen L., Morgillo, Floriana, Nadal, Ernest, Mazzoni, Francesca, Agustoni, Francesco, Bar, Jair, Grosso, Federica, Avrillon, Virginie, Patel, Jyoti D., Gomes, Fabio, Ibrahim, Ehab, Trama, Annalisa, Bettini, Anna C., Barlesi, Fabrice, Dingemans, Anne-Marie, Wakelee, Heather, Peters, Solange, Horn, Leora, Garassino, Marina Chiara, and Torri, Valter

Published
2022
Full Text
View/download PDF

11. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non–Small-cell Lung Cancer With Different Prognostic Significance

Author

Iams, Wade T, Yu, Hui, Shyr, Yu, Patil, Tejas, Horn, Leora, McCoach, Caroline, Kelly, Karen, Doebele, Robert C, and Camidge, D Ross

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Lung, Lung Cancer, Cancer, Clinical Trials and Supportive Activities, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins p21(ras), Retrospective Studies, Survival Analysis, Chemotherapy-responsive, KRAS clinical syndromes, Metastatic, NSCLC, Soft tissue metastasis, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundUnsuccessful KRAS-specific treatment approaches in non-small-cell lung cancer (NSCLC) might reflect underlying disease heterogeneity. We sought to define clinical "syndromes" within advanced KRAS mutant NSCLC to improve future clinical trials and create a clinical framework for future molecular development.Patients and methodsTo test a series of a priori hypotheses regarding KRAS-mutant NSCLC clinical syndromes, we conducted a multi-institutional retrospective medical record review. Survival probabilities were estimated using the Kaplan-Meier model. Between-group differences were assessed using the log-rank test. Multivariate Cox regression analyses and Wilcoxon rank sum testing were used to assess progression-free survival and overall survival (OS) differences.ResultsAmong 218 patients with advanced KRAS-mutant NSCLC, OS and progression-free survival with first-line chemotherapy did not differ by intrathoracic versus extrathoracic spread, smoking intensity, or the specific KRAS mutation. Metastatic disease at diagnosis resulted in significantly worse OS than recurrent, unresectable disease (median OS, 14.6 vs. 40.9 months; P = .001). Among the patients with metastatic disease at diagnosis, nonscalp, soft tissue metastases (syndrome X; 6% of cases; 95% confidence interval [CI], 2.5%-10.1%) signified a poor prognosis (median OS, 7.5 vs. 15.9 months for the controls; P = .021). The response to first-line chemotherapy (syndrome Y; 41% of cases; 95% CI, 32.3%-50.6%) signified a good prognosis (median OS, 26.7 vs. 11.9 months; P = .002). The overlap between these 2 syndromes was minimal (2 of 111). Multivariate analysis confirmed these observations. The hazard ratio for death for syndromes X and Y was 2.64 (95% CI, 1.13-6.14) and 0.45 (95% CI, 0.28-0.76), respectively.ConclusionChemotherapy-responsive disease and nonscalp, soft tissue spread might represent distinct clinical syndromes within KRAS-mutant NSCLC. The molecular biology underlying this heterogeneity warrants future studies.

Published
2018

12. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Author

Wakelee, Heather A, Dahlberg, Suzanne E, Keller, Steven M, Tester, William J, Gandara, David R, Graziano, Stephen L, Adjei, Alex A, Leighl, Natasha B, Aisner, Seena C, Rothman, Jan M, Patel, Jyoti D, Sborov, Mark D, McDermott, Sean R, Perez-Soler, Roman, Traynor, Anne M, Butts, Charles, Evans, Tracey, Shafqat, Atif, Chapman, Andrew E, Kasbari, Samer S, Horn, Leora, Ramalingam, Suresh S, Schiller, Joan H, and ECOG-ACRIN

Subjects
Clinical Research, Lung Cancer, Lung, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Patient Selection, Pneumonectomy, Survival Analysis, Treatment Outcome, ECOG-ACRIN, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health.

Published
2017

13. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)

Author

Patel, Jyoti D., Lee, Ju-Whei, Carbone, David P., Wagner, Henry, Shanker, Anil, de Aquino, Maria Teresa P., Horn, Leora, Johnson, Melissa L., Gerber, David E., Liu, Jane Jijun, Das, Millie S., Al-Nsour, Mohammed Ali, Dakhil, Christopher S.R., Ramalingam, Suresh, and Schiller, Joan H.

Published
2020
Full Text
View/download PDF

15. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, Marina Chiara, Whisenant, Jennifer G, Huang, Li-Ching, Trama, Annalisa, Torri, Valter, Agustoni, Francesco, Baena, Javier, Banna, Giuseppe, Berardi, Rossana, Bettini, Anna Cecilia, Bria, Emilio, Brighenti, Matteo, Cadranel, Jacques, De Toma, Alessandro, Chini, Claudio, Cortellini, Alessio, Felip, Enriqueta, Finocchiaro, Giovanna, Garrido, Pilar, Genova, Carlo, Giusti, Raffaele, Gregorc, Vanesa, Grossi, Francesco, Grosso, Federica, Intagliata, Salvatore, La Verde, Nicla, Liu, Stephen V, Mazieres, Julien, Mercadante, Edoardo, Michielin, Olivier, Minuti, Gabriele, Moro-Sibilot, Denis, Pasello, Giulia, Passaro, Antonio, Scotti, Vieri, Solli, Piergiorgio, Stroppa, Elisa, Tiseo, Marcello, Viscardi, Giuseppe, Voltolini, Luca, Wu, Yi-Long, Zai, Silvia, Pancaldi, Vera, Dingemans, Anne-Marie, Van Meerbeeck, Jan, Barlesi, Fabrice, Wakelee, Heather, Peters, Solange, and Horn, Leora

Published
2020
Full Text
View/download PDF

16. Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

Author

Iams, Wade T., Kopparapu, Prasad R., Yan, Yingjun, Muterspaugh, Anel, Zhao, Zhiguo, Chen, Heidi, Cann, Christopher, York, Sally, Horn, Leora, Ancell, Kristin, Wyman, Kenneth, Bertucci, Caterina, Shaffer, Tristan, Hodsdon, Lauren A., Garg, Kavita, Hosseini, Seyed Ali, Lim, Lee P., and Lovly, Christine M.

Published
2020
Full Text
View/download PDF

17. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Author

Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M., Garon, Edward B., Gettinger, Scott, Goldberg, Sarah B., Herbst, Roy S., Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A., Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A., and Scagliotti, Giorgio V.

Published
2020
Full Text
View/download PDF

19. New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Author

Poirier, John T., George, Julie, Owonikoko, Taofeek K., Berns, Anton, Brambilla, Elisabeth, Byers, Lauren A., Carbone, David, Chen, Huanhuan J., Christensen, Camilla L., Dive, Caroline, Farago, Anna F., Govindan, Ramaswamy, Hann, Christine, Hellmann, Matthew D., Horn, Leora, Johnson, Jane E., Ju, Young S., Kang, Sumin, Krasnow, Mark, Lee, James, Lee, Se-Hoon, Lehman, Jonathan, Lok, Benjamin, Lovly, Christine, MacPherson, David, McFadden, David, Minna, John, Oser, Matthew, Park, Keunchil, Park, Kwon-Sik, Pommier, Yves, Quaranta, Vito, Ready, Neal, Sage, Julien, Scagliotti, Giorgio, Sos, Martin L., Sutherland, Kate D., Travis, William D., Vakoc, Christopher R., Wait, Sarah J., Wistuba, Ignacio, Wong, Kwok Kin, Zhang, Hua, Daigneault, Jillian, Wiens, Jacinta, Rudin, Charles M., and Oliver, Trudy G.

Published
2020
Full Text
View/download PDF

20. Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

Author

Hong, Tae Hee, primary, Hwang, Soohyun, additional, Dasgupta, Abhijit, additional, Abbosh, Christopher, additional, Hung, Tiffany, additional, Bredno, Jörg, additional, Walker, Jill, additional, Shi, Xiaojin, additional, Milenkova, Tsveta, additional, Horn, Leora, additional, Choi, Joon Young, additional, Lee, Ho Yun, additional, Cho, Jong Ho, additional, Choi, Yong Soo, additional, Shim, Young Mog, additional, Chai, Shoujie, additional, Rhodes, Kate, additional, Roychowdhury-Saha, Manami, additional, Hodgson, Darren, additional, Kim, Hong Kwan, additional, and Ahn, Myung, additional

Published
2024
Full Text
View/download PDF

22. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas, Dobelbower, Michael, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Swanson, Scott J, Stevenson, James, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Rare Diseases, Lung, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Humans, Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pleural Neoplasms, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Published
2016

23. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Author

Ready, Neal E., Ott, Patrick A., Hellmann, Matthew D., Zugazagoitia, Jon, Hann, Christine L., de Braud, Filippo, Antonia, Scott J., Ascierto, Paolo A., Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D. Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K., and Spigel, David R.

Published
2020
Full Text
View/download PDF

25. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas J, Dobelbower, M Chris, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Stevenson, James, Swanson, Scott J, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Cancer, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Docetaxel, Humans, Immunosuppressive Agents, Immunotherapy, Lung Neoplasms, Nivolumab, Practice Guidelines as Topic, Survival Rate, Taxoids, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016

27. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Author

Horn, Leora, Whisenant, Jennifer G., Wakelee, Heather, Reckamp, Karen L., Qiao, Huan, Leal, Ticiana A., Du, Liping, Hernandez, Jennifer, Huang, Vincent, Blumenschein, George R., Waqar, Saiama N., Patel, Sandip P., Nieva, Jorge, Oxnard, Geoffrey R., Sanborn, Rachel E., Shaffer, Tristan, Garg, Kavita, Holzhausen, Allison, Harrow, Kimberly, Liang, Chris, Lim, Lee P., Li, Mark, and Lovly, Christine M.

Published
2019
Full Text
View/download PDF

28. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Author

Antonia, Scott J, Borghaei, Hossein, Ramalingam, Suresh S, Horn, Leora, De Castro Carpeño, Javier, Pluzanski, Adam, Burgio, Marco A, Garassino, Marina, Chow, Laura Q M, Gettinger, Scott, Crinò, Lucio, Planchard, David, Butts, Charles, Drilon, Alexander, Wojcik-Tomaszewska, Joanna, Otterson, Gregory A, Agrawal, Shruti, Li, Ang, Penrod, John R, and Brahmer, Julie

Published
2019
Full Text
View/download PDF

29. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Author

Spigel, David R., McCleod, Michael, Jotte, Robert M., Einhorn, Lawrence, Horn, Leora, Waterhouse, David M., Creelan, Ben, Babu, Sunil, Leighl, Natasha B., Chandler, Jason C., Couture, Felix, Keogh, George, Goss, Glenwood, Daniel, Davey B., Garon, Edward B., Schwartzberg, Lee S., Sen, Rohini, Korytowsky, Beata, Li, Ang, Aanur, Nivedita, and Hussein, Maen A.

Published
2019
Full Text
View/download PDF

35. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

Author

Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, and Soria, Jean-Charles

Published
2018
Full Text
View/download PDF

37. Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

Author

Lander, Eric M., primary, Li, Xuanyi, additional, Huang, Li-Ching, additional, Cass, Amanda S., additional, Iams, Wade T., additional, Skotte, Emily A., additional, Whisenant, Jennifer G., additional, Ramirez, Robert A., additional, York, Sally J., additional, Osterman, Travis J., additional, Lewis, Jennifer A., additional, Lovly, Christine M., additional, Shyr, Yu, additional, and Horn, Leora, additional

Published
2023
Full Text
View/download PDF

39. Scientific Advances in Thoracic Oncology 2016

Author

Soo, Ross A., Stone, Emily C.A., Cummings, K. Michael, Jett, James R., Field, John K., Groen, Harry J.M., Mulshine, James L., Yatabe, Yasushi, Bubendorf, Lukas, Dacic, Sanja, Rami-Porta, Ramon, Detterbeck, Frank C., Lim, Eric, Asamura, Hisao, Donington, Jessica, Wakelee, Heather A., Wu, Yi-Long, Higgins, Kristin, Senan, Suresh, Solomon, Benjamin, Kim, Dong-Wan, Johnson, Melissa, Yang, James C.H., Sequist, Lecia V., Shaw, Alice T., Ahn, Myung-Ju, Costa, Daniel B., Patel, Jyoti D., Horn, Leora, Gettinger, Scott, Peters, Solange, Wynes, Murry W., Faivre-Finn, Corinne, Rudin, Charles M., Tsao, Anne, Baas, Paul, Kelly, Ronan J., Leighl, Natasha B., Scagliotti, Giorgio V., Gandara, David R., Hirsch, Fred R., and Spigel, David R.

Published
2017
Full Text
View/download PDF

41. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

42. Cancer of the Lung

Author

Araujo, Luiz H., primary, Horn, Leora, additional, Merritt, Robert E., additional, Shilo, Konstantin, additional, Xu-Welliver, Meng, additional, and Carbone, David P., additional

Published
2020
Full Text
View/download PDF

46. Clinician Perspectives on Current Issues in Lung Cancer Drug Development

Author

Waqar, Saiama N., Bonomi, Philip D., Govindan, Ramaswamy, Hirsch, Fred R., Riely, Gregory J., Papadimitrakopoulou, Vassiliki, Kazandjian, Dickran, Khozin, Sean, Larkins, Erin, Dickson, Dane J., Malik, Shakun, Horn, Leora, Ferris, Andrea, Shaw, Alice T., Jänne, Pasi A., Mok, Tony S.K., Herbst, Roy, Keegan, Patricia, Pazdur, Richard, and Blumenthal, Gideon M.

Published
2016
Full Text
View/download PDF

47. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Author

Antonia, Scott J, López-Martin, José A, Bendell, Johanna, Ott, Patrick A, Taylor, Matthew, Eder, Joseph Paul, Jäger, Dirk, Pietanza, M Catherine, Le, Dung T, de Braud, Filippo, Morse, Michael A, Ascierto, Paolo A, Horn, Leora, Amin, Asim, Pillai, Rathi N, Evans, Jeffry, Chau, Ian, Bono, Petri, Atmaca, Akin, Sharma, Padmanee, Harbison, Christopher T, Lin, Chen-Sheng, Christensen, Olaf, and Calvo, Emiliano

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results